Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/10/2025

Management of Enhertu-Induced Diarrhea

Grade-Based Management Algorithm

  • The American Society of Clinical Oncology recommends initiating loperamide immediately at 4 mg followed by 2 mg every 2-4 hours or after each unformed stool, with a maximum daily dose of 16 mg, for patients experiencing diarrhea while taking Enhertu (trastuzumab deruxtecan) 1, 2
  • For uncomplicated diarrhea, defined as grade 1-2 without fever, severe cramping, bloody stools, or signs of dehydration, the European Society for Medical Oncology suggests continuing Enhertu at the current dose while managing symptoms 2
  • The National Comprehensive Cancer Network recommends starting loperamide 4 mg initially, then 2 mg every 2-4 hours or after each unformed stool (maximum 16 mg/day), and implementing dietary modifications immediately, such as eliminating all lactose-containing products, avoiding coffee, alcohol, spices, and reducing insoluble fiber intake 1, 2, 3, 4
  • The American College of Gastroenterology advises ensuring oral hydration with isotonic solutions (1 L/day minimum) and instructing patients to record stool frequency and report if diarrhea persists >48 hours or worsens 1, 2

Grade 2 Diarrhea Persisting >48 Hours

  • The European Society for Medical Oncology recommends adding codeine 30 mg twice daily (can increase to 60 mg four times daily short-term) if diarrhea continues despite maximum loperamide dosing for 48 hours 5
  • The American Society of Clinical Oncology suggests considering holding Enhertu temporarily and obtaining stool cultures to rule out infectious causes (C. difficile, Salmonella, E. coli, Campylobacter) 2, 5

Grade 3-4 Diarrhea (Complicated)

  • The National Comprehensive Cancer Network advises hospitalizing immediately for aggressive management, discontinuing Enhertu until resolution, and administering IV fluids and correcting electrolyte abnormalities, targeting urine output >0.5 mL/kg/h 2, 3
  • The American College of Gastroenterology recommends continuing loperamide at maximum doses (16 mg/day), adding octreotide 100-150 mcg subcutaneously or IV three times daily, and starting empiric antibiotics (fluoroquinolone) while awaiting stool cultures 1, 2, 3

Resuming Enhertu After Diarrhea Resolution

  • The European Society for Medical Oncology suggests restarting Enhertu at a reduced dose per prescribing information once diarrhea improves to grade ≤1 or returns to baseline, and tapering and discontinuing codeine when restarting Enhertu to avoid constipation 5
  • The American Society of Clinical Oncology recommends continuing loperamide prophylactically at lower doses if needed 5

Critical Pitfalls to Avoid

  • The National Comprehensive Cancer Network advises not delaying loperamide initiation, as early intervention prevents progression to severe, complicated diarrhea requiring hospitalization 2
  • The American College of Gastroenterology warns against using loperamide or opioids in grade 3-4 diarrhea with suspected colitis, as this can precipitate toxic megacolon or paralytic ileus 1, 3
  • The American Society of Clinical Oncology recommends monitoring for dehydration aggressively, as HER2-targeted antibody-drug conjugates like Enhertu combined with prior chemotherapy can cause rapid fluid losses leading to prerenal injury 2, 3

Special Considerations for Enhertu

  • The European Society for Medical Oncology notes that while specific Enhertu diarrhea data is limited, the management principles follow established chemotherapy-induced diarrhea guidelines 1, 2
  • The American College of Gastroenterology suggests considering budesonide 9 mg once daily for loperamide-refractory diarrhea without bloody stools, though prophylactic use is not recommended 1, 3